Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740488 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL18173280 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL15885825 | 0.79 | HPGD (0.48) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL27152815 | 0.79 | KDM4E (0.43) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL1126884 | 0.77 | KMT2A (0.44) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL16740459 | 0.77 | KMT2A (0.46) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL27063134 | 0.76 | TP53 (0.45) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL27145901 | 0.75 | KDM4E (0.43) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL15952633 | 0.75 | ATM (0.47) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL12990968 | 0.74 | LMNA (0.50) | ALDH1A1MEN1KMT2ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167098-A1 | HETEROCYCLIC COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167098-A1 | HETEROCYCLIC COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-9550796-B2 | Pyrrolopyrrolone derivatives and their use as BET inhibitors | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| US-20160280719-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | NOVARTIS AG (CH) | 2016-09-29 | — | — | US | disclosed |
| EP-3071571-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | Novartis AG (CH) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015075665-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | NOVARTIS AG (CH) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280719-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | BET1, PHKB, TMPO | ALDH1A1 2915/4885MEN1 2685/4885KMT2A 2712/4885 |
| US-20230167098-A1 | HETEROCYCLIC COMPOUND | CYP11B2, CYP4F11, CYP11B1 | ALDH1A1 465/4885MEN1 511/4885KMT2A 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.